Kristjan Karason

List of Publications by Year in Descending Order

68 papers	6,719 citations	22 h-index	71 g-index
71 ext. papers	7,743 ext. citations	5.8 avg, IF	4.98 L-index

#	Paper	IF	Citations
68	Heart failure in childhood cancer survivors-a systematic review protocol.. *Systematic Reviews*, **2022**, 11, 54	3	
67	Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: a Swedish single center experience.. *BMC Cardiovascular Disorders*, **2022**, 22, 192	2.3	0
66	Somatostatin Receptor Positron Emission Tomography/Computed Tomography in Giant Cell Myocarditis: A Promising Approach to Molecular Myocardial Inflammation Imaging.. *Circulation: Cardiovascular Imaging*, **2021**, CIRCIMAGING121013551	3.9	2
65	Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart Transplantation. *Journal of the American College of Cardiology*, **2021**, 78, 2425-2435	15.1	0
64	Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls. *American Journal of Transplantation*, **2021**,	8.7	1
63	Durable circulatory support with a paracorporeal device as an option for pediatric and adult heart failure patients. *Journal of Thoracic and Cardiovascular Surgery*, **2021**, 161, 1453-1464.e4	1.5	7
62	COVID-19 in solid organ transplant recipients: A national cohort study from Sweden. *American Journal of Transplantation*, **2021**, 21, 2762-2773	8.7	14
61	Initial Report From a Swedish High-volume Transplant Center After the First Wave of the COVID-19 Pandemic. *Transplantation*, **2021**, 105, 108-114	1.8	29
60	Heart failure development in obesity: underlying risk factors and mechanistic pathways. *ESC Heart Failure*, **2021**, 8, 356-367	3.7	3
59	Prognostic significance of BMI after PCI treatment in ST-elevation myocardial infarction: a cohort study from the Swedish Coronary Angiography and Angioplasty Registry. *Open Heart*, **2021**, 8,	3	1
58	Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myocarditis: a systematic review and meta-analysis. *Clinical Research in Cardiology*, **2021**, 1	6.1	4
57	Incidental cardiac findings on somatostatin receptor PET/CT: What do they indicate and are they of clinical relevance?. *Journal of Nuclear Cardiology*, **2021**, 1	2.1	1
56	Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation. *European Heart Journal*, **2021**,	9.5	2
55	Registry reports in COVID-19 patients: juggling with big data, poor data, and no data. *Kidney International*, **2020**, 98, 1618	9.9	1
54	Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure. *Growth Hormone and IGF Research*, **2020**, 55, 101359	2	0
53	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. *Clinical Transplantation*, **2020**, 34, e13984	3.8	7
52	Heart failure development in obesity: mechanistic pathways. *European Heart Journal*, **2020**, 41, 3485	9.5	6

51	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. *Journal of Cardiovascular Pharmacology*, **2020**, 76, 4-22	3.1	12
50	Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. *European Journal of Heart Failure*, **2020**, 22, 739-750	12.3	11
49	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. *ESC Heart Failure*, **2020**, 7, 567-576	3.7	1
48	Inflammatory cardiomyopathies: short- and long-term outcomes after heart transplantation-a protocol for a systematic review and meta-analysis. *Heart Failure Reviews*, **2020**, 25, 481-485	5	2
47	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. *Cardiac Failure Review*, **2020**, 6, e19	4.2	15
46	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. *Transplantation*, **2020**, 104, 154-164	1.8	12
45	Early post-transplant elevated pulmonary artery pressure predicts adverse outcome in cardiac recipients. *IJC Heart and Vasculature*, **2020**, 26, 100438	2.4	0
44	Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic. *Infectious Diseases*, **2020**, 52, 830-837	3.1	19
43	Haemophagocytic lymphohistiocytosis after heart transplantation: a case report. *European Heart Journal - Case Reports*, **2020**, 4, 1-4	0.9	
42	Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles. *Brain*, **2020**, 143, 2406-2420	11.2	7
41	High-intensity interval training and health-related quality of life in de novo heart transplant recipients - results from a randomized controlled trial. *Health and Quality of Life Outcomes*, **2020**, 18, 283	3	6
40	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. *International Journal of Cardiology*, **2019**, 297, 83-90	3.2	21
39	Surgical obesity treatment and the risk of heart failure. *European Heart Journal*, **2019**, 40, 2131-2138	9.5	28
38	The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection. *Journal of Heart and Lung Transplantation*, **2019**, 38, 1097-1103	5.8	11
37	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. *Journal of Clinical Medicine*, **2019**, 8,	5.1	9
36	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. *Cardiac Failure Review*, **2019**, 5, 155-161	4.2	8
35	Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia. *Circulation*, **2019**, 139, 2198-2211	16.7	28
34	Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial. *Transplantation*, **2019**, 103, 781-788	1.8	4

33	Cardiac arrest in Wilson's disease after curative liver transplantation: a life-threatening complication of myocardial copper excess?. *ESC Heart Failure*, **2019**, 6, 228-231	3.7	7
32	Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression. *American Journal of Transplantation*, **2019**, 19, 1050-1060	8.7	5
31	Renal function and outcome after heart transplantation. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 155, 1593-1604.e1	1.5	33
30	Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. *Journal of Cardiovascular Pharmacology*, **2018**, 71, 129-136	3.1	23
29	Clinical features and determinants of VO in heart transplant recipients. *World Journal of Transplantation*, **2018**, 8, 188-197	2.3	5
28	Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients. *Circulation: Heart Failure*, **2018**, 11, e004050	7.6	22
27	Continuous improvement in outcome after heart transplantation - Long-term follow-up after three decades of experience. *International Journal of Cardiology*, **2017**, 231, 188-194	3.2	11
26	Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE). *Clinical Transplantation*, **2017**, 31, e13038	3.8	2
25	Are biventricular assist devices underused as a bridge to heart transplantation in patients with a high risk of postimplant right ventricular failure?. *Journal of Thoracic and Cardiovascular Surgery*, **2017**, 153, 360-367.e1	1.5	12
24	Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. *European Heart Journal Supplements*, **2017**, 19, C22-C28	1.5	7
23	Measured and not estimated glomerular filtration rate should be used to assess renal function in heart transplant recipients. *Nephrology Dialysis Transplantation*, **2016**, 31, 1182-9	4.3	14
22	Design and rationale of the HITTS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia. *American Heart Journal*, **2016**, 172, 96-105	4.9	10
21	Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. *Transplant International*, **2016**, 29, 819-29	3	26
20	Bariatric Surgery and the Risk of New-Onset Atrial Fibrillation in Swedish Obese Subjects. *Journal of the American College of Cardiology*, **2016**, 68, 2497-2504	15.1	115
19	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. *International Journal of Cardiology*, **2016**, 218, 150-157	3.2	47
18	How should we manage early tricuspid valve regurgitation after heart transplantation?. *International Journal of Cardiology*, **2016**, 214, 191-3	3.2	3
17	Successful heart transplantation from a donor with takotsubo syndrome. *International Journal of Cardiology*, **2015**, 195, 82-4	3.2	9
16	Early onset cardiomyopathy in females with Danon disease. *Neuromuscular Disorders*, **2015**, 25, 493-501	2.9	25

15	GH and the cardiovascular system: an update on a topic at heart. *Endocrine*, **2015**, 48, 25-35	4	85
14	Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report. *Journal of Medical Case Reports*, **2015**, 9, 180	1.2	6
13	Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA - Journal of the American Medical Association*, **2014**, 311, 2297-304	27.4	652
12	Sleep apnea modifies the long-term impact of surgically induced weight loss on cardiac function and inflammation. *Obesity*, **2013**, 21, 698-704	8	14
11	The influence of body composition, fat distribution, and sustained weight loss on left ventricular mass and geometry in obesity. *Obesity*, **2012**, 20, 605-11	8	28
10	Bariatric surgery and long-term cardiovascular events. *JAMA - Journal of the American Medical Association*, **2012**, 307, 56-65	27.4	1069
9	Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. *Sleep*, **2007**, 30, 703-10	1.1	115
8	Effects of bariatric surgery on mortality in Swedish obese subjects. *New England Journal of Medicine*, **2007**, 357, 741-52	59.2	3425
7	Effort-related calf pain in the obese and long-term changes after surgical obesity treatment. *Obesity*, **2005**, 13, 137-45		10
6	Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. *European Heart Journal*, **2003**, 24, 1500-5	9.5	28
5	Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. *Archives of Internal Medicine*, **2000**, 160, 1797-802		118
4	Heart rate variability in obesity and the effect of weight loss. *American Journal of Cardiology*, **1999**, 83, 1242-7	3	285
3	Effects of obesity and weight loss on cardiac function and valvular performance. *Obesity*, **1998**, 6, 422-9		84
2	Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. *BMJ: British Medical Journal*, **1997**, 315, 912-6		119
1	Blockade of the glucocorticoid receptor with RU 486: effects in vitro and in vivo on human adipose tissue lipoprotein lipase activity. *Obesity*, **1995**, 3, 233-40		31